How I Treat: Secondary Acute Myeloid Leukemia
Secondary acute myeloid leukemia (sAML) has traditionally been used to designate any AML disease arising from an antecedent hematologic disorder or followi
Secondary acute myeloid leukemia (sAML) has traditionally been used to designate any AML disease arising from an antecedent hematologic disorder or followi
The impact of a coach who sought and created deep connection resonates across USF and college basketball.
What comes after being declared “cancer-free”? Libby Znaimer and the medical panel of experts examine the physical and emotional challenges of the next step …
Abstract. Establishing a strategy for sequencing of T cell redirecting therapies for relapsed/refractory multiple myeloma (RRMM) is a pressing clinical need. We longitudinally tracked the…
Tolkien’s vision of the long defeat provides unexpected resources for true hope.
Outcomes for acute myeloid leukemia have improved significantly in the last decade with the approval of novel therapeutics targeting diverse vulnerabilitie
In 2017, the Washington Post, under a more emboldened Bezos, unveiled its new slogan, “Democracy Dies in Darkness.” On Friday the Post hid what should…
Diffuse large B-cell lymphoma (DLBCL) is an aggressive, yet curable malignancy, but older patients are at higher risk of relapsed disease as they may not…
Secondary acute myeloid leukemia (sAML) has traditionally been used to designate any AML disease arising from an antecedent hematologic disorder or followi
Venetoclax received full approval in October 2020 for use in older, unfit patients with acute myeloid leukemia (AML) combined with either hypomethylating a
Key PointsTreatment with ruxolitinib and interferon alfa-2a is well tolerated with anemia as the main cause for dose reduction.Treatment with ruxolitinib a